Reporter brief
12-week RCT found metformin's effects on insulin sensitivity and mitochondrial function differed by baseline insulin resistance status
What happened
A 12-week double-blind, placebo-controlled RCT in 148 non-diabetic subjects stratified by baseline insulin sensitivity tested whether metformin improves outcomes in insulin-resistant individuals but worsens them in insulin-sensitive individuals. The study assessed insulin sensitivity, glucose regulation, aging biomarkers, and mitochondrial function via skeletal muscle biopsy pre- and post-intervention.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
148 subjects recruited from two sites (Oklahoma Medical Research Foundation and University of Wisconsin-Madison), free of type 2 diabetes, stratified to insulin sensitive or insulin resistant groups
- Design
- Rct
- Sample
- 148
- Journal
- Oklahoma Medical Research Foundation
- Published
- Jul 2, 2026
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Metformin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.